JPMorgan Upgrades Baldwin Insurance on Potential Take-Private Deal
JPMorgan upgraded Baldwin Insurance from Neutral to Overweight and raised its price target to $28 after the company hired advisors for a potential take-private transaction.
NOTRELOAD AI
Breakthrough LSD-Derived Drug DT120 Shows Dramatic Antidepressant Effect in Phase 3 Trial
Definium’s DT120 pill showed strong fast and lasting depression relief in Phase 3, with good safety and big symptom cuts.
FDA Aligns with REGENXBIO on Accelerated Approval Pathway for NAVSUNLI Gene Therapy in Hunter Syndrome
FDA reverses course and agrees to review existing data for NAVSUNLI gene therapy in Hunter syndrome.
Leerink Initiates Outperform on Altimmune: Pemvidutide Poised for MASH Success with $10 Target
Pemvidutide demonstrates strong MASH resolution, weight loss, and cardiometabolic benefits, with significant analyst upside.
Fervo Energy, NVIDIA & PNNL Launch AI-Powered Digital Twin Platform for Geothermal
It combines real-time field data, physics-based modeling, and NVIDIA Omniverse to optimize power generation.
CRH to Acquire Arcosa for $8.5 Billion in Largest Deal in Its History
The deal boosts exposure to aggregates, energy transmission, and infrastructure megatrends.